These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 32634126)

  • 1. SARS-CoV-2 viral load and antibody responses: the case for convalescent plasma therapy.
    Casadevall A; Joyner MJ; Pirofski LA
    J Clin Invest; 2020 Oct; 130(10):5112-5114. PubMed ID: 32634126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
    Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
    JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What are protective antibody responses to pandemic SARS-CoV-2?
    Henderson JP
    J Clin Invest; 2020 Dec; 130(12):6232-6234. PubMed ID: 33055417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics of viral load and antibody response in relation to COVID-19 severity.
    Wang Y; Zhang L; Sang L; Ye F; Ruan S; Zhong B; Song T; Alshukairi AN; Chen R; Zhang Z; Gan M; Zhu A; Huang Y; Luo L; Mok CKP; Al Gethamy MM; Tan H; Li Z; Huang X; Li F; Sun J; Zhang Y; Wen L; Li Y; Chen Z; Zhuang Z; Zhuo J; Chen C; Kuang L; Wang J; Lv H; Jiang Y; Li M; Lin Y; Deng Y; Tang L; Liang J; Huang J; Perlman S; Zhong N; Zhao J; Malik Peiris JS; Li Y; Zhao J
    J Clin Invest; 2020 Oct; 130(10):5235-5244. PubMed ID: 32634129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
    Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
    Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Passive Immunity for Coronavirus Disease 2019: A Commentary on Therapeutic Aspects Including Convalescent Plasma.
    Lindholm PF; Ramsey G; Kwaan HC
    Semin Thromb Hemost; 2020 Oct; 46(7):796-803. PubMed ID: 32526774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2.
    Anderson DE; Tan CW; Chia WN; Young BE; Linster M; Low JH; Tan YJ; Chen MI; Smith GJD; Leo YS; Lye DC; Wang LF
    Emerg Microbes Infect; 2020 Dec; 9(1):900-902. PubMed ID: 32380903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19.
    Zhang L; Pang R; Xue X; Bao J; Ye S; Dai Y; Zheng Y; Fu Q; Hu Z; Yi Y
    Aging (Albany NY); 2020 Apr; 12(8):6536-6542. PubMed ID: 32320384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2.
    Zhou G; Zhao Q
    Int J Biol Sci; 2020; 16(10):1718-1723. PubMed ID: 32226289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perspectives of Immune Therapy in Coronavirus Disease 2019.
    Gasparyan AY; Misra DP; Yessirkepov M; Zimba O
    J Korean Med Sci; 2020 May; 35(18):e176. PubMed ID: 32383371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation.
    Li L; Tong X; Chen H; He R; Lv Q; Yang R; Zhao L; Wang J; Xu H; Liu C; Chen G; Chen S; Li C; Qiao J; Yang J; Wu Y; Liu Z
    Transfusion; 2020 Aug; 60(8):1765-1772. PubMed ID: 32627216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19.
    Hueso T; Pouderoux C; Péré H; Beaumont AL; Raillon LA; Ader F; Chatenoud L; Eshagh D; Szwebel TA; Martinot M; Camou F; Crickx E; Michel M; Mahevas M; Boutboul D; Azoulay E; Joseph A; Hermine O; Rouzaud C; Faguer S; Petua P; Pommeret F; Clerc S; Planquette B; Merabet F; London J; Zeller V; Ghez D; Veyer D; Ouedrani A; Gallian P; Pacanowski J; Mékinian A; Garnier M; Pirenne F; Tiberghien P; Lacombe K
    Blood; 2020 Nov; 136(20):2290-2295. PubMed ID: 32959052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges of Convalescent Plasma Therapy on COVID-19.
    Zhao Q; He Y
    J Clin Virol; 2020 Jun; 127():104358. PubMed ID: 32305026
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019.
    Zeng QL; Yu ZJ; Gou JJ; Li GM; Ma SH; Zhang GF; Xu JH; Lin WB; Cui GL; Zhang MM; Li C; Wang ZS; Zhang ZH; Liu ZS
    J Infect Dis; 2020 Jun; 222(1):38-43. PubMed ID: 32348485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea.
    Ahn JY; Sohn Y; Lee SH; Cho Y; Hyun JH; Baek YJ; Jeong SJ; Kim JH; Ku NS; Yeom JS; Roh J; Ahn MY; Chin BS; Kim YS; Lee H; Yong D; Kim HO; Kim S; Choi JY
    J Korean Med Sci; 2020 Apr; 35(14):e149. PubMed ID: 32281317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Why should we use convalescent plasma for COVID-19?
    Franchini M
    Eur J Intern Med; 2020 Jul; 77():150-151. PubMed ID: 32425365
    [No Abstract]   [Full Text] [Related]  

  • 18. Non-infectious status indicated by detectable IgG antibody to SARS-CoV-2.
    Denning DW; Kilcoyne A; Ucer C
    Br Dent J; 2020 Oct; 229(8):521-524. PubMed ID: 33097885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq.
    Rasheed AM; Fatak DF; Hashim HA; Maulood MF; Kabah KK; Almusawi YA; Abdulamir AS
    Infez Med; 2020 Sep; 28(3):357-366. PubMed ID: 32920571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of COVID-19 Virus Infection by Convalescent Plasma.
    Cheraghali AM; Abolghasemi H; Eshghi P
    Iran J Allergy Asthma Immunol; 2020 May; 19(S1):3-6. PubMed ID: 32534509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.